Delix Therapeutics Inc. has been awarded a $320,000 grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, to support the advancement of DLX-007.
Idorsia Pharmaceuticals Ltd. researchers have prepared and tested new thiazoloaryl-methyl substituted cyclic hydrazine-N-carboxamide derivatives acting as orexin OX1 and OX2 receptor antagonists. They are reported to be useful for the treatment of substance abuse and dependence, anxiety, cognitive, sleep, eating and mood disorders.
Organophosphorus compounds (OPs) include several types of chemical compounds used as pesticides, herbicides or nerve agents in chemical warfare that, once in the body, act by inhibiting acetylcholinesterase (AChE) functions leading to an excessive increase of acetylcholine that ultimately causes death after respiratory failure.
The FDA has awarded orphan drug designation to Neoimmunetech Inc.'s NT-I7 (efineptakin alfa, rhIL-7-hyFc) for the treatment of acute radiation syndrome (ARS). NT-I7, a novel long-acting recombinant human IL-7, has the potential to rapidly recover and improve the immune response following a high dose of radiation exposure.
Research at the University of Florida has led to the identification of compounds acting as dual dopamine transporter (DAT) and sigma receptor (sigma nonopioid intracellular receptor 1 [σ1, SIGMAR1] and sigma intracellular receptor 2 [σ2, TMEM97]) antagonists reported to be useful for the treatment of methamphetamine dependence and cocaine dependency.
Researchers from Inventage Lab Inc. have presented preclinical data for its naltrexone-loaded microspheres, named IVL-3004, developed as long-acting injectable using the proprietary IVL-Drugfluidic technology platform.
The preBötzinger complex (preBötC) appears to play a relevant role in opiate-induced respiratory depression, as suggested by studies in animal models. However, limited research concerning preBötC physiology in humans has been conducted, and no human in vitro models of the preBötC exist.
Phoenix Pharmalabs Inc. has reported findings from in vivo studies that demonstrated that the company’s lead compound, PPL-138, reduced symptoms of post-traumatic stress disorder (PTSD) and decreased alcohol consumption in a rat model of PTSD/alcohol use disorder (AUD). The studies were conducted at the University of Oklahoma Health Sciences Center and Florida Atlantic University under a grant from the U.S. Department of Defense.
Antoxa Corp. and Swiftpharma BV have signed an exclusive collaboration agreement to support the development and commercialization of a plant-made monoclonal antibody against ricin exposure.
Ceramedix Holding LLC has been awarded a phase IIB Small Business Innovation Research (SBIR) grant valued at approximately US$3 million by the National Institute of Allergy and Infectious Diseases (NIAID) to support the evaluation of the non-clinical pharmacology of its lead drug candidate. The anti-ceramide antibody is in development through the National Institutes of Health (NIH) as a potential therapeutic to mitigate and/or treat illness due to radiation exposure.